Busulfan has been previously only available in an oral formulation due to its poor water solubility. We report the results of a phase I study of multiple escalating doses of intravenous busulfan (Spartaject Busulfan, Orphan Europe, Paris, France) for myeloablation prior to stem cell transplantation (SCT) in 12 patients with chronic myeloid leukemia, acute myeloid leukemia or acute lymphocytic leukemia. One patient received allogeneic SCT; the other 11 patients received autologous SCT. The first six patients received i.v. busulfan diluted in 50 ml of 0.9% normal saline and the last six patients received busulfan in a 500-ml 5% dextrose solution. All patients experienced profound myelosuppression and all but one demonstrated hematopoietic engraftment. Toxicity was mild or moderate and there were no toxic deaths attributable to busulfan. Of note, there were no cases of veno-occlusive disease of the liver. Busulfan plasma concentrations were determined by gas chromatography with electron capture detection and showed little intrapatient variability. In most cases there was no significant difference between the first and last dose PK parameters. These data suggest that dose adjustment based on first dose PK data could allow uniformity of busulfan dosing for patients receiving SCT. Leukemia (2000Leukemia ( ) 14, 1954Leukemia ( -1959 
Introduction
Total body irradiation (TBI) combined with cyclophosphamide (Cy) has for many years been a standard myeloablative therapy for patients undergoing hematopoietic stem cell transplantation (SCT). However, not infrequently, busulfan (Bu) has been used as an alternative to TBI in combination with cyclophosphamide (BuCy). Bu is a bifunctional alkylating agent previously only available in an oral formulation due to its poor solubility in water. 1 Clinical studies of Bu disposition following oral dosing in both children and adults have found a high degree of inter-and intra-patient variability when assessed by pharmacokinetic parameters such as the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C max ). 2, 3 Some of the factors which have been suggested to underlie this variability are circadian rhythmicity, age, disease, drug interactions, alteration in hepatic function and recently, Bu bioavailability 3 which can vary up to six-fold in children and two-fold in adults. 2 In hematopoietic SCT with Bu, outcome has been related at least in part to the AUC and average steady-state concentration. 1 Excessively high Bu AUC has been associated with an increased incidence of hepatic veno-occlusive disease, while low levels have been associated both with a higher relapse risk in patients with chronic myeloid leukemia (CML) and with graft rejection in allogeneic transplantation. [4] [5] [6] [7] [8] More recently, mean plasma concentrations of Bu (Meanconc) have been correlated with survival post-allogeneic SCT and with transplant-related mortality (TRM) in both allogeneic and autologous transplantation. 9 Recent studies have reported that the pharmacokinetics of high-dose Bu in SCT are age-dependent: with the usual dosage of 16 mg/kg over 4 days, systemic exposure is two to four times lower in children than in adults. These data have suggested that the dose of Bu in children should be calculated on the basis of the body surface area (BSA) rather than body weight. 3, [10] [11] [12] An intravenous preparation of Bu could overcome these dosing variability problems and additionally allow dose adjustment during therapy. We report the results of a phase I pharmacokinetic study of multiple escalating doses of intravenous Bu as myeloablation prior to stem cell transplantation in patients with leukemia.
Patients and methods

Intravenous Bu
The drug is a formulated Bu product known as Spartaject Busulfan. It was supplied by Orphan Europe (Paris, France). The qualitative composition of Spartaject Busulfan consists of Bu, 1,2 dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2 dimyristoyl-sn-glycero-3-phosphocholine (DMPC), mannitol and sodium acetate trihydrate. Spartaject technology is a proprietary system, which allows compounds that are insoluble or poorly soluble in water to be delivered intravenously without the need for organic solvents. To achieve this, microparticles of a given drug are encapsulated in a mixture of purified phospholipids such that a microsuspension is formed. This suspension is distinctively different from liposomes with different biological and pharmacokinetic behavior.
Spartaject Busulfan is supplied as a sterile lyophilized preparation in single usage strength of 25 mg per vial. It is reconstituted with water for injection and diluted with 5% dextrose or 0.9% normal saline. The first six patients received Spartaject Busulfan diluted in 50 ml of 0.9% normal saline and the subsequent six patients received a 500-ml 5% dextrose solution.
The stability of the drug, once reconstituted, is 8 h. Intravenous infusions take between 30 min (50-ml infusion) and 60 min (500-ml infusion).
Treatment design
This was an open label, non-randomized, uncontrolled phase I study of Bu alone or in combination with cyclophosphamide as myeloablation before autologous or allogeneic SCT. 
Pharmacokinetic studies
Pharmacokinetics studies were performed after the first and last intravenous doses. No PK studies were done after oral administration of busulfan. Blood samples (5 ml) were collected immediately before the infusion and at 10, 15, 30 min during the infusion. After infusion stop, samples were collected at 2, 5, 10, 20, 45, 90 min and at 3, 4 and 5-6 h. The full sampling protocol was followed after the first and the last dose of infusion. Samples were also collected during the oral administration, to determine the mean minimum concentration of Bu (trough level). The blood was immediately centrifuged at 2000 g and plasma was frozen at −20°C until assay.
Bu plasma concentrations were determined by gas chromatography with electron capture detector (1,5-bis methane sulfonoxy pentane was used as internal standard). Bu and the internal standard were converted to 1,4 di-idobutane and 1,5 di-idopentane respectively prior to analysis. 13 Pharmacokinetic measurements were performed at Huddinge University Hospital, Huddinge, Sweden.
Pharmacokinetic parameters studied included: AUC, area under the curve vs time (ng × h/l); C max , maximum concentration (ng/ml); t . , elimination half-life (h); and Meanconc, median concentration (ng/ml). Pharmacokinetic modeling and parameter estimates were performed using WinNonlin ver. 3.0 (Pharsight, Mountain View, CA, USA). The area under timeplasma concentration curves (AUC) were calculated using the trapezoidal method with extrapolation beyond the 6th hour for the first dose only, while the elimination half-life was calculated from the slope of the terminal phase of elimination.
Patients
From July 1997 to July 1999 a total of 12 patients was enrolled in this phase I trial. All patients gave written informed consent and the protocol was approved by the Hammersmith Hospital Research Ethics Committee. Clinical characteristics are summarized in Table 1 . Ten patients had chronic myeloid leukemia (CML) (seven late chronic phase, two accelerated phase and one second chronic phase after lymphoid blastic transformation) and two had acute leukemia in first complete remission (one acute lymphocytic leukemia (ALL) and one acute myeloid leukemia (AML)). Median age was 46 years (21-55). Nine CML patients underwent autologous peripheral blood stem cell transplant. For three CML patients this was Leukemia their second autografting procedure. One CML patient underwent a second allogeneic SCT from the original donor. All 10 CML patients (including the allogeneic SCT patient) were conditioned with Bu alone (16 mg/kg) as described elsewhere.
14 Two patients with acute leukemia received an autologous peripheral blood stem cell transplant using Bu (16 mg/kg) and cyclophosphamide (120 mg/kg) (BuCy).
Due to several initial problems with precipitation of the drug during the reconstitution and infusion of Spartaject Busulfan, some alterations of the planned treatment schedule were made. Patient No. 2 received 0.8 mg/kg doses, due to the use of ideal instead of actual body weight. Patient No. 3 received eight intravenous doses instead of the planned 12 doses. Patient No. 6 received only four i.v. doses instead of the planned 16 doses. The method of dilution was changed in that Spartaject Busulfan was diluted in 500 ml of 5% dextrose solution for patient Nos 7 to 12. These last six patients received 16 i.v. doses as planned. The actual number of i.v. infusions is summarized in Table 1 .
Results
Clinical outcome
The clinical outcome in these 12 patients is shown in Table 1 . All patients experienced profound myelosuppression following administration of Spartaject Busulfan and all but one patient demonstrated myeloid engraftment after infusion of stem cells. One patient did not engraft (see below), and one other patient needed a stem cell top-up infusion 28 days after the first one to achieve platelet engraftment. The median time to neutrophil engraftment (Ͼ0.5 × 10 9 /l) was 17 (11-36) days. The median time to platelet recovery of Ͼ20 × 10 9 /l and Ͼ50 × 10 9 /l was 18 (0-41) and 35 (0-150+) days, respectively. Of note two patients did not develop thrombocytopenia below 20 × 10 9 /l at any stage. One patient failed to engraft. He was treated with 16 intravenous doses of Spartaject Busulfan and became pancytopenic on day +8. The total peripheral blood stem cell dose which had been infused on day 0 was 1.85 × 10 8 nucleated cells (NC)/kg. These cells had been collected 30 months after diagnosis (5 years before this second SCT) following a first autograft and were 95% Philadelphia negative. On day +20, a second stem cell infusion consisting of 8.97 × 10 8 NC/kg was given. The patient developed gastrointestinal and intracranial hemorrhage and died on day +39 without evidence of engraftment.
At the time of last evaluation, with a median follow-up of 10 months, 10 of the 12 patients are alive. Of the nine patients with CML who had an autograft two have died from disease progression and intracranial hemorrhage, respectively, one has subsequently undergone unrelated allogeneic SCT, one has progressed into accelerated phase, three remain with chronic phase disease, and two are in complete hematological remission. The CML patient who underwent a second allogeneic SCT remains in remission after follow-up of more than 18 months. One patient with AML relapsed 10 months after the autologous SCT and then received an allogeneic SCT from his HLA identical brother. The patient with ALL remains in complete remission. 
Toxicity
Spartaject Busulfan therapy was well tolerated (Table 2) , and there were no directly attributable toxic deaths. However, one patient died due to complications related to the procedure (see above). All patients received prophylaxis with oral phenytoin and none experienced seizures. Nausea and vomiting were generally moderate and six of the 12 patients tolerated the regimen without significant discomfort. All patients showed some evidence of stomatitis and/or mucositis. Oral intake was significantly reduced in 10 patients, and they received parenteral nutritional support. Patients undergoing allogeneic SCT or BuCy conditioning had the same degree of mucositis as the Bu-only autoSCT group. There were no cases of veno-occlusive disease of the liver (VOD). Five patients developed minor abnormalities of liver function tests (LFT). Four patients had significant elevation in serum bilirubin but did not fulfil the criteria for VOD. Two patients developed mild renal impairment but this was reversible in both cases. One patient developed a mild episode of pericarditis, which resolved with conservative measures. No patients experienced any significant toxicity affecting the lungs, central nervous system or bladder. One patient developed a venous thrombosis associated with an intravascu- 
Pharmacokinetic studies
The data from the PK studies are summarized in Table 3 . Figure 1 shows an example of a typical plasma concentration over time curve after the first and last infusions.
Area under the curve versus time (AUC):
The AUC was measured after the first and last (4th dose in two patients, 8th in two, 12th in one and 16th in seven) intravenous doses. The median AUC for the first i.v. dose was 6173.5 ng × h/ml. The standard deviation (s.d.) was 1949.9 ng × h/ml. The median AUC for the last i.v. dose was 6570.6 ng × h/ml with an s.d. of 1341.1 ng × h/ml. All AUCs were between 4000 and 9000 ng × h/ml except for the first dose in patient No. 2, who received a dose of less than 0.8 mg/kg as a result of using ideal instead of actual body weight. All but six AUC (75%) were below the 8000 ng × h/ml upper limit and involved only four patients (25%).
Maximum concentration (C max ):
The calculated C max ranged between 1092 ng/ml and 3466 ng/ml. The median C max for the first dose was 1787 (s.d. 614) ng/ml and for the last i.v. dose was 1738.5 (s.d. 407) ng/ml. Only one patient had a C max above 3000 ng/ml. This and five other patients received the infusion of Spartaject Busulfan using a 50-ml infusion and a syringe driver. When the infusion method was changed to a 500-ml solution (infused over 1 h), the median C max for the last six patients was 1485 (s. 
Mean concentration (Meanconc):
The mean concentration (trough concentration) based on the measurement of the concentration immediately before each dose was calculated on all 12 patients and ranged between 257 and 737 ng/ml with a median of 526.5 (s.d. 148.6) ng/ml. Only one patient's Meanconc was greater than 700 ng/ml.
Discussion
One of the major problems with the use of Bu has been that the therapeutic window is narrow, but correlation of AUC between different oral doses is low. 2, 8, [15] [16] [17] In many patients the short dosing interval leads to variability in compartmental fitting of concentration data, which makes estimates of t . and model-derived AUC unreliable. 18, 19 In this study we have observed low intra-patient differences in Bu disposition. The data have shown that the AUC after the first and last infusions were very similar (Figure 1 ). The median AUC was 6173.5 ng × h/ml (2357 to 8472) for the first dose and 6324.5 ng × h/ml (4154 to 8721) for the last dose. Furthermore, little variation was observed in patients who received 4, 8, 12 or 16 i.v. doses of Spartaject Busulfan. Only four patients had an AUC above 8000 ng × h/ml. The number of patients in this study was too small to allow predictions of reliability of dose reductions. However, if the reproducibility of the AUC is confirmed in a larger study, it could allow for dose reduction if necessary and the consequent minimization of toxicity. Such dose modification may be beneficial since in one study patients with a high AUC who did not receive dose adjustment had a 75% incidence of VOD. 20 The half-life of Spartaject Busulfan was similar to that which has been reported with oral Bu in adults 2, 8 and with other intravenous preparations. [21] [22] [23] [24] There was no evidence of drug accumulation or decline over time within the 16 i.v. doses.
Leukemia
C max was high in three patients (Ͼ2500 ng/ml). This could have been related to the precipitation problem experienced when Spartaject Busulfan was dissolved in 50 ml of 0.9% saline and infused via a syringe pump (which necessitated continuous agitation of the syringe). The concentration of Bu in the syringe was found to be higher at the end than at the start of the infusion, which could have led to higher plasma concentrations. This effect did not occur when Spartaject Busulfan was diluted in 500 ml of 5% dextrose solution, and the C max values were very homogenous in the subsequent six patients.
The mean concentration (Meanconc) for our patients varied between 257 and 737 ng/ml. Only one patient's Meanconc was higher than 700 ng/ml and this patient survived the SCT. In a previous study, Ljungman et al 9 showed that patients who died before day 100 had significantly higher mean Bu concentrations than patients surviving beyond day 100 (719 ng/ml vs 589 ng/ml).
An important finding of this study was the low toxicity observed. All patients experienced mucositis, but it was mild to moderate in most cases. Nausea and vomiting were generally mild and one half of patients did not experience significant discomfort. This toxicity profile appears lower than observed with many other regimens. Of potential significance was the absence of hepatic VOD in this series, although there was a small number of patients in the study. It is possible that the lack of high-dose cyclophosphamide use in 10 of the 12 patients was of relevance to this. 6, 9 Other organ toxicity was mild. One patient failed to engraft and four others developed late-onset thrombopenia. Due to the limited number of patients a detrimental effect of Spartaject Busulfan of the bone marrow stroma cannot be excluded.
Several other intravenous formulations of Bu have been developed in recent years. [21] [22] [23] [24] In one study, Bu was dissolved in a cosolvent mixture of anhydrous dimethylacetamide (DMA), polyethylene glycol 400 (PEG400), and water at a ratio of 1:2:2 (v/v/v), to achieve a Bu concentration of 3 mg/ml. 21 This preparation has been used in clinical trials with similar results to Spartaject Busulfan. The group in Huddinge has been pioneering the use of liposomal Bu with promising results in a rat model. Liposomal Bu is prepared using L-alpha-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol. The preparation appears to target bone marrow and spleen, with no accumulation in the liver or other organs notable for toxicity following conventional Bu therapy. 22, 24 In summary, this study suggests that the use of intravenous Bu preparations will allow accurate and effective pharmacokinetic-guided dose adjustment. This may lead to an improvement in the outcome of patients undergoing SCT, with reduced therapy-related toxicity.
